Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
Blood Research
; : S1-S4, 2021.
Article
in En
| WPRIM
| ID: wpr-889653
Responsible library:
WPRO
ABSTRACT
Despite substantially improved survival with rituximab-based treatment regimens, there is an unmet medical need for better treatments of B-cell lymphoma, particularly for patients with relapsed or refractory disease. Retreatment with rituximab exerts a limited effect in these patients, and platinum-based salvage treatment followed by autologous stem cell transplantation remains the only curative option. Recent strategies have focused on targeting novel B-cell surface markers, inhibiting B-cell receptor signaling, and enhancing the cytotoxicity of effector cells. The current article will review the recent progress in immunochemotherapy targeting other than CD20 for B-cell lymphomas.
Full text:
1
Index:
WPRIM
Language:
En
Journal:
Blood Research
Year:
2021
Type:
Article